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Objectives: CTEPH is a progressive and commonly fatal disease. A systematic 
literature review was conducted to synthesize evidence on mortality and survival 
in patients with inoperable CTEPH or residual/recurrent pulmonary hyperten-
sion (PH) after pulmonary endarterectomy (PEA). MethOds: Using specific search 
terms, we systematically searched for MEDLINE- and EMBASE-indexed studies on 
the epidemiology of CTEPH in various regions (including Western Europe, North 
America, New Zealand, or Australia) without temporal limits. Among these stud-
ies, we identified those that reported mortality and/or survival for patients with 
inoperable CTEPH or residual/recurrent PH post-PEA. These studies then under-
went analytical narrative synthesis. Results: In all, 71 articles met the criteria 
for acceptance into the review. Of these, 21 described mortality or survival in 
patients with inoperable CTEPH or residual/recurrent PH post-PEA. The propor-
tion of patients with inoperable disease was 27%–41% in seven registries and 
retrospective studies in Europe. The proportion of patients who underwent PEA 
was 59%–69% in two Canadian studies and 10%–65% (median 50%) in 11 European 
studies. Among studies with ≥ 18 months of follow-up, mortality was higher in 
patients with inoperable CTEPH (13.4%–58%, with seven of 10 studies reporting 
mortality rates of 13.3%–21.4%) than among those with residual/recurrent PH 
post-PEA (7.4% after a mean follow-up of 50 months). Overall survival was lower 
among patients with inoperable CTEPH than among those with residual/recurrent 
PH post-PEA. Survival rates for inoperable CTEPH were 73%–93% at one year (10 
studies), 41%–88% at three years (nine studies), and 53%–88% at five years (five 
studies). In contrast, patients with residual/recurrent PH post-PEA had five-year 
survival rates of 89.9%–100% (three studies). cOnclusiOns: Inoperable CTEPH 
carries a particularly poor prognosis, with survival rates lower even than those 
for patients who have residual/recurrent PH following PEA.
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Objectives: Among patients with acute myeloid leukemia (AML), the DACO-016 
randomized study showed reduction in mortality for DACOGEN®(decitabine, DAC) 
compared with treatment choice (TC): at primary analysis the Hazard Ratio (HR) 
was 0.85 (95% CI: 0.69- 1.04; stratified log-rank p= 0.108). With two interim analyses, 
2-sided alpha was adjusted to 0.0462. With one year additional follow-up the HR 
reached 0.82 (nominal p= 0.037). These data, together with significant outcomes in 
secondary endpoints and a positive benefit-risk resulted in approval of DACOGEN 
in the EU, however not in the US. With the primary analysis only showing a strong 
trend, the French Haute Autorité de Santé negated a mortality benefit. Though pre-
specified, the log-rank test could be considered not optimal to assess the observed 
survival difference because of the non-proportional hazard nature of the survival 
curves. We applied the Wilcoxon test as a sensitivity analysis. MethOds: Patients 
(age ≥ 65 years, ineligible for chemotherapy) were randomized to DAC (N= 242) or TC 
(N= 243). For testing the observed treatment effect, Wilcoxon-test is considered more 
powerful in the context of non-proportional hazard curves compared to the log-rank 
test, as the former assigns more weight to earlier events. Results: A total of 108 
(44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively 
crossed over to subsequent disease modifying therapies at progression, which might 
impact the survival beyond the median with resultant converging curves (and dis-
proportional hazards). The Wilcoxon-test stratified by baseline age, cytogenetic-risk 
and ECOG performance status showed a significant improvement in OS with DAC 
(7.7 [6.2; 9.2] months) versus TC (5.0 [4.3; 6.3] months) (p= 0.0456). cOnclusiOns: 
Wilcoxon-test indicated significant increase in survival for DAC vs TC in patients 
with AML compared to log-rank test at primary analysis.
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Objectives: Deferasirox is an oral iron chelator that has demonstrated efficacy in 
reducing excess liver iron concentration (LIC) in iron overloaded non-transfusion 
dependent thalassemia (NTDT) patients. This analysis estimated the budget impact 
of reimbursing deferasirox in Greece. MethOds: An open cohort budget impact 
model was developed from the Greek health care system perspective over 5 years. 
Comparators included deferoxamine, deferiprone, and combination therapy (defer-
oxamine plus deferiprone). NTDT prevalence, drug acquisition and administration 
costs were from Greece (2013 € ). No discounting was applied. Deferasirox clinical 
inputs were derived from the THALASSA trial. Rate of reduction in LIC (decrease 
of 26%) was applied each year for deferasirox. This was assumed the same for all 
comparators. Patients remained on treatment until the 3 mg Fe/gr dw discontinua-
tion threshold for LIC was reached. Treatment was reinitiated when LIC increased 
above 5 mg Fe/gr dw. Base case starting age was 10 years. Sensitivity analysis was 
performed on key model inputs. Results: A total of 280 patients with NTDT were 
estimated to be treated with iron chelation per year. With no deferasirox, total drug 
acquisition and administration costs were € 3,545,406 and € 11,889,133, respec-
tively. With the introduction of deferasirox, acquisition costs increased by 62% to € 
5,738,323 and administration costs decreased by 58% to € 4,993,474. Total expendi-
ture decreased by over 30% representing cost savings of € 4,702,742 over 5 years. 
Results were sensitive to acquisition costs, administration costs for deferoxamine, 
treatment efficacy and discontinuation threshold. cOnclusiOns: Reimbursement 
of deferasirox in NTDT resulted in cost savings to the Greek health care system. 
with the Cochrane Collaboration guidelines and the Polish Agency for Health 
Technology Assessment recommendations. Calculations were performed using 
the StatsDirect®2.6.8 statistical package. Results: : As a result of the systematic 
literature search 2 primary RCTs (subtype II A), satisfying the inclusion criteria 
were found: Cappellini 2006 (patients with beta-thalassaemia) and Vichinsky 2006 
(patients with sickle cell disease). The results of the performed analysis proved 
that once-daily oral deferasirox showed similar efficacy to parenteral deferoxamine 
therapy in terms of decreased in LIC (liver iron concentration) and SF (serum fer-
ritin). Treatment adherence was similar in both DSX and DFO groups. Safety analysis 
showed that deferasirox was safe and well-tolerated therapy. The most frequent 
adverse events in the deferasirox group were diarrhea, nausea, vomiting, abdominal 
pain and skin rash. In most cases, analysed adverse events were mild and transient. 
Discontinuation rates were similar in both DSX and DFO arms. cOnclusiOns: 
Deferasirox represents an important once-daily oral agent for the treatment of 
chronic iron overload due to blood transfusions. Once-daily oral deferasirox has 
acceptable tolerability and similar efficacy to parental deferoxamine in reducing 
iron burden in transfused paediatric patients. Moreover, deferasirox improves 
patients’ quality of life, may improve patient’s compliance with treatment and 
reduces morbidity and mortality from iron overload.
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Objectives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune con-
dition characterized by increased platelet destruction and suboptimal platelet 
production, resulting in low platelet counts (thrombocytopenia). Romiplostim has 
shown efficacy in increasing platelet counts. The objective of this study was to 
conduct meta-analysis and present total evidence for Romiplostim for treatment 
of ITP. MethOds: For this meta-analysis we included randomized controlled tri-
als (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs 
that compared romiplostim versus placebo for management of ITP, had a treat-
ment duration of at least 24 weeks, were doubleblind (patients and investigators 
blinded) and reported data on platelet response. A systematic literature search 
for Etanercept trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, interventions, 
year, and the two outcomes overall and durable platelet response rate. For meta-
analysis, random effects and fixed effects models were used to obtain cumulative 
statistics. Results: Two RCTs with a total of 125 patients were identified. The 
pooled response rates for Romiplostim for overall platelet response rate were 
82% (95% CI 73%-90%); and for durable platelet response rate were 48% (95% CI 
26%-71%). The pooled response rates for placebo for overall platelet response rate 
were 7% (95% CI 0%-15%), and for durable platelet response rate were 2% (95% CI 
0%-4%). For overall platelet response rate the cumulative relative risk with placebo 
versus Romiplostim was 0.09 (95% CI 4%-14%). For durable platelet response rate, 
the cumulative relative risk with placebo versus Romiplostim was 0.03 (95% CI 
0%-6%). cOnclusiOns: Meta-analysis shows Romiplostim offers patients with 
Immune idiopathic thrombocytopenia an effective therapeutic option for increas-
ing platelet counts.
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Objectives: Adult patients who receive general anesthesia may not remain totally 
unconscious during surgery despite of anesthetics and analgesics care received. The 
retention of memory due to intraoperative awareness may cause serious clinical 
complications, requiring 1071 patients monitored to prevent the occurrence of one 
event. The proper conventional maintenance of general anesthesia is assessed with 
clinical signs or expired gases (ETAC/ETAG/ETCO2). Bi-Spectral Index Monitoring or 
BIS Sensor is a neurophysiological evaluation system that continually analyzes EEG 
to determine the level of intraoperative awareness. MethOds: We have made a lit-
erature search in PubMed to identify systematic reviews and randomized controlled 
trials that studied level of consciousness intraoperative or postoperative memory 
when used these alternatives of anesthetic monitoring. Results: We have found 
nine RCT and two systematic reviews published until April 2013 and conducted our 
own meta-analysis on seven trials. Two studies were excluded from the synthesis for 
not presenting the outcome of primary interest. Three RCT of moderate heterogene-
ity showed no difference in the occurrence of intraoperative awareness between the 
BIS group and the ETAC/ETAG/ETCO2 group. The quality of evidence was considered 
high in one study, moderate and low in the others (26,490 patients, I2 = 45.9%, RR = 
1.28, 95% CI = 0.54 to 3.03, p = 0.57). Four clinical monitoring control group studies 
with no heterogeneity showed that the sensor BIS was more effective, requiring 
between 71 and 167 patients monitored for an event of intraoperative awareness 
avoided. The quality of evidence of the studies was considered high (7,779 patients, 
I2 = 0.0%, RR = 0.42, 95% CI = 0.27 to 0.65, p = 0, 0.0001). cOnclusiOns: Clinical 
trials published until April 2013 showed favorable results in patient-oriented out-
comes of BIS group when compared to clinical monitoring group but not to ETAC/
ETAG/ETCO2 group.
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